Efficacy and safety of adjunctive aripiprazole in major depressive disorder in older patients: a pooled subpopulation analysis.
Efficacy and safety of adjunctive aripiprazole in major depressive disorder in older patients: a pooled subpopulation analysis.
复制标题
辅助阿立哌唑治疗老年重度抑郁症的疗效和安全性：亚群汇总分析。
DOI：
10.1002/gps.2564
复制
发表时间：
2011
影响因子：
4
通讯作者：
Berman,RobertM
中科院分区：
文献类型：
--
作者：
Steffens,DavidC;Nelson,JCraig;Eudicone,JamesM;Andersson,Candace;Yang,Huyuan;Tran,Quynh-Van;Forbes,RobertA;Carlson,BeritX;Berman,RobertM
ObjectivesTo evaluate efficacy and safety of adipipiprazole compared with standard antidepressant therapy（ADT）for older patients with major depression disorder（MDD）who demonstrated an incomplete response to standard antidepressant monetary.MethodsData from three similar 14-wk studies（a 8-wk prospective ADT treatment phase and a 6-wk randomized，double-blind phase）of adiprazole augmentation were mixed for thispost-adiprazole analysis.定义了两个年龄组：年轻患者（18-49岁）和老年患者（50-67岁）。老年患者组进一步分为三个亚组：50-55岁、56-60岁和61-67岁。有效性终点是从前瞻性阶段结束（第8周）至终点（第14周，末次观察值结转法（LOCF））的蒙哥马利-韦斯伯格抑郁评定量表（MADRS）总分的平均变化。缓解定义为MADRS总分≤10在endpoint.Results409老年患者（安慰剂，n= 198;阿立哌唑，n= 211）和679年轻患者（安慰剂，n= 341;阿立哌唑，n= 338）被纳入本分析。接受阿立哌唑治疗的老年患者在第14周的MADRS总分改善显著高于安慰剂（-10.0vs.−6.4;p< 0.001; LOCF），与年轻患者中观察到的改善相似。阿立哌唑组的缓解率明显高于安慰剂组，老年组（32.5%比17.1%;p< 0.001）和年轻组（26.9%比16.4%;p< 0.001）。静坐不能是最常见的不良事件，在老年人（17.1%）和年轻人（26.0%）patient group. ConclusionsAdjective阿立哌唑是有效的改善抑郁症状的老年患者，50-67岁，MDD谁有一个标准的抗抑郁药物反应不足。版权所有© 2010约翰威利父子有限公司.
ObjectivesTo evaluate the efficacy and safety of adjunctive aripiprazole compared with standard antidepressant therapy (ADT) for older patients with major depressive disorder (MDD) who demonstrated an incomplete response to standard antidepressant monotherapy.MethodsData from three similar 14‐week studies (an 8‐week prospective ADT treatment phase and a 6‐week randomized, double‐blind phase) of aripiprazole augmentation were pooled for thispost hocanalysis. Two age groups were defined: younger patients (aged 18–49 years) and older patients (aged 50–67 years). The older patient group was further divided into three subgroups: 50–55, 56–60, and 61–67 years. The efficacy endpoint was the mean change in Montgomery–Åsberg Depression Rating Scale (MADRS) total score from end of the prospective phase (Week 8) to endpoint (Week 14, last observation carried forward (LOCF)). Remission was defined as MADRS total score ≤10 at endpoint.ResultsFour hundred and nine older patients (placebo,n= 198; aripiprazole,n= 211) and 679 younger patients (placebo,n= 341; aripiprazole,n= 338) were included in this analysis. Older patients receiving aripiprazole demonstrated significantly greater improvement in MADRS total scoreversusplacebo at Week 14 (−10.0vs. −6.4;p< 0.001; LOCF), similar to the improvement seen in younger patients. Remission rates were significantly higher with aripiprazoleversusplacebo in older (32.5%vs. 17.1%;p< 0.001) and younger (26.9%vs. 16.4%;p< 0.001) patients. Akathisia was the most common adverse event in both the older (17.1%) and younger (26.0%) patient groups.ConclusionsAdjunctive aripiprazole was effective in improving depressive symptoms in older patients, 50–67 years, with MDD who have had an inadequate response to standard antidepressant medication. Copyright © 2010 John Wiley & Sons, Ltd.